You are here

P&T January 2014

Features

Pharmacovigilance Forum
In three case histories, patients’ sprue-like symptoms improved when olmesartan (Benicar) therapy was withheld.
Compounding and Tracing Provisions Seek to Improve Quality of Drug Supply
The Drug Quality and Security Act is intended to prevent the sale of contaminated compounded agents, but the way in which facilities will be regulated is still unclear. Many safeguards will need to be implemented.
Are They Worth the Risk?
Dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) offer better efficacy over warfarin, and minimal monitoring is needed. However, there is no effective reversal agent, these new agents are not indicated for all patients, and there is limited information available about drug–drug and drug–disease interactions.
Meeting Highlights
Agents for Hypertension, Heart Failure, and Acute Myocardial Infarction

Topics include medications used in hypertension, heart failure, renal dysfunction, and myocardial infarction.

Departments

Medication Errors
Following the guidelines for standard order sets minimizes incorrect prescribing.
Prescription: Washington
Pharmacists want the FDA to standardize REMS programs.

FDA approvals, drug indications, and updates

Obinutuzumab (Gazyva) for chronic lymphocytic leukemia; ibrutinib (Imbruvica) for mantle-cell lymphoma; and sofosbuvir (Sovaldi) for chronic hepatitis C infection

Drug Forecast
Ingenol mebutate gel (Picato) for actinic keratoses